| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3981110 | Clinical Radiology | 2016 | 7 Pages |
•Aortic enhacement is highly related to hemodynamic parameters from the test bolus.•Test bolus based contrast protocols achieve target aortic attenuation with improved uniformity.•Patients scanned at 100 kVp has a reduction in the mean contrast flow rate close to 3 ml/s.
AimTo develop and validate a test bolus (TB)-based quantitative model to create an individualised contrast medium injection protocol for use at coronary computed tomography angiography (CCTA) to improve patient-to-patient uniformity of intracoronary attenuation.Materials and methodsIn the model-building phase, 175 patients who underwent CCTA using a traditional contrast medium injection protocol were recruited. A personalised injection equation was proposed according to the relationship between aortic enhancement and the haemodynamic parameters obtained from the TB. In the model-validation phase, a target aortic enhancement of 350 HU was set. Two hundred and fifteen additional CCTA examinations were performed using the proposed personalised injection model. Comparisons of inter-individual variability between the traditional and the proposed personalised injection protocol were performed.ResultsIn the model-building phase, a high positive correlation between aortic enhancement and the haemodynamic parameters obtained from the TB was found. As a result, a personalised injection equation was determined using linear regression. In the model-validation phase, the average aortic enhancement was 350.5 HU, without significant differences from the preset level. Using the TB-based personalised injection protocol, inter-individual variability of aortic enhancement was significantly reduced (71.8 versus 38.9 HU, p<0.001) and patients who were scanned at 100 kVp had a reduction in the average contrast medium flow rate from 4.1 to 3.2 ml/s (p<0.001).ConclusionsThe proposed TB-based injection protocol can achieve a desired preset and stable aortic enhancement.
